{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:53:33Z","timestamp":1790916813903,"version":"4.1.0"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,1,1]],"date-time":"2026-01-01T00:00:00Z","timestamp":1767225600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,30]],"date-time":"2026-06-30T00:00:00Z","timestamp":1782777600000},"content-version":"vor","delay-in-days":180,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100000964","name":"Arthritis National Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000964","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001501","name":"University Grants Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001501","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001332","name":"Council for Scientific and Industrial Research, South Africa","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001332","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment and Research Communications"],"published-print":{"date-parts":[[2026]]},"DOI":"10.1016\/j.ctarc.2026.101303","type":"journal-article","created":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:58:31Z","timestamp":1783036711000},"page":"101303","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["Molecular determinants of Bortezomib sensitivity and resistance in multiple myeloma"],"prefix":"10.1016","volume":"48","author":[{"given":"Jahir","family":"Hossain","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debopriya","family":"Choudhury","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soham","family":"Bhattacharyya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brahmachari","family":"Vedeshachaitanya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2295-4062","authenticated-orcid":false,"given":"Pushkar","family":"Malakar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ctarc.2026.101303_bib0001","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1038\/s41572-024-00529-7","article-title":"Multiple myeloma","volume":"10","author":"Malard","year":"2024","journal-title":"Nat. Rev. Dis. Primers"},{"key":"10.1016\/j.ctarc.2026.101303_bib0002","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1146\/annurev-cancerbio-061421-014236","article-title":"Next-generation therapies for multiple myeloma","volume":"8","author":"Meermeier","year":"2024","journal-title":"Annu. Rev. Cancer Biol."},{"key":"10.1016\/j.ctarc.2026.101303_bib0003","doi-asserted-by":"crossref","first-page":"154","DOI":"10.4049\/jimmunol.2300212","article-title":"The proteasome inhibitor bortezomib induces p53-dependent apoptosis in activated B cells","volume":"212","author":"Ochoa","year":"2024","journal-title":"J. Immunol."},{"key":"10.1016\/j.ctarc.2026.101303_bib0004","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1007\/s10238-025-01713-z","article-title":"Impact of proteostasis workload on sensitivity to proteasome inhibitors in multiple myeloma","volume":"25","author":"Sedlacek","year":"2025","journal-title":"Clin. Exp. Med."},{"key":"10.1016\/j.ctarc.2026.101303_bib0005","doi-asserted-by":"crossref","first-page":"111","DOI":"10.3390\/ph16010111","article-title":"Review on Bortezomib resistance in multiple myeloma and potential role of emerging technologies","volume":"16","author":"Kozalak","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ctarc.2026.101303_bib0006","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1186\/2050-7771-1-13","article-title":"The resistance mechanisms of proteasome inhibitor bortezomib","volume":"1","author":"L\u00fc","year":"2013","journal-title":"Biomark. Res."},{"key":"10.1016\/j.ctarc.2026.101303_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2024.123125","article-title":"Bortezomib in cancer therapy: mechanisms, side effects, and future proteasome inhibitors","volume":"358","author":"Sogbein","year":"2024","journal-title":"Life Sci."},{"key":"10.1016\/j.ctarc.2026.101303_bib0008","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1186\/s12943-025-02472-x","article-title":"Targeting proteostasis for cancer therapy: current advances, challenges, and future perspectives","volume":"24","author":"Zhang","year":"2025","journal-title":"Mol. Cancer"},{"key":"10.1016\/j.ctarc.2026.101303_bib0009","doi-asserted-by":"crossref","first-page":"2489","DOI":"10.1182\/blood-2007-08-104950","article-title":"Molecular basis of bortezomib resistance: proteasome subunit beta5 (PSMB5) gene mutation and overexpression of PSMB5 protein","volume":"112","author":"Oerlemans","year":"2008","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.ctarc.2026.101303_bib0010","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1007\/s11864-024-01273-6","article-title":"Acquired bortezomib resistance in multiple myeloma: from mechanisms to strategy","volume":"25","author":"Li","year":"2024","journal-title":"Curr. Treat. Options. Oncol."},{"key":"10.1016\/j.ctarc.2026.101303_bib0011","doi-asserted-by":"crossref","DOI":"10.1186\/s43556-024-00188-w","article-title":"Multiple myeloma: signaling pathways and targeted therapy","volume":"5","author":"Lu","year":"2024","journal-title":"Mol. Biomed."},{"key":"10.1016\/j.ctarc.2026.101303_bib0012","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.3390\/cancers13071686","article-title":"Emerging therapeutic strategies to overcome drug resistance in multiple myeloma","volume":"13","author":"Davis","year":"2021","journal-title":"Cancers. (Basel)"},{"key":"10.1016\/j.ctarc.2026.101303_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e33091","article-title":"Pathways to therapy resistance: the sheltering effect of the bone marrow microenvironment to multiple myeloma cells","volume":"10","author":"Bhowmick","year":"2024","journal-title":"Heliyon."},{"key":"10.1016\/j.ctarc.2026.101303_bib0014","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2219978120","article-title":"Proteasome inhibitor bortezomib stabilizes and activates p53 in hematopoietic stem\/progenitors and double-negative T cells in vivo","volume":"120","author":"Xue","year":"2023","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ctarc.2026.101303_bib0015","doi-asserted-by":"crossref","first-page":"3836","DOI":"10.1021\/acsomega.1c04726","article-title":"P53: stability from the ubiquitin\u2013Proteasome system and specific 26S proteasome inhibitors","volume":"7","author":"Do Patrocinio","year":"2022","journal-title":"ACS. Omega"},{"key":"10.1016\/j.ctarc.2026.101303_bib0016","doi-asserted-by":"crossref","DOI":"10.1093\/jmcb\/mjac074","article-title":"The ARTS of p53-dependent mitochondrial apoptosis","volume":"14","author":"Hao","year":"2023","journal-title":"J. Mol. Cell Biol."},{"issue":"10","key":"10.1016\/j.ctarc.2026.101303_bib0017","doi-asserted-by":"crossref","first-page":"1717","DOI":"10.1038\/cdd.2017.96","article-title":"p53-mediated suppression of BiP triggers BIK-induced apoptosis during prolonged endoplasmic reticulum stress","volume":"24","author":"L\u00f3pez","year":"2017","journal-title":"Cell Death. Differ."},{"key":"10.1016\/j.ctarc.2026.101303_bib0018","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3892\/or.2021.7933","article-title":"Endoplasmic reticulum stress, cell death and tumor: association between endoplasmic reticulum stress and the apoptosis pathway in tumors (Review)","volume":"45","author":"Fu","year":"2021","journal-title":"Oncol. Rep."},{"key":"10.1016\/j.ctarc.2026.101303_bib0019","doi-asserted-by":"crossref","first-page":"895","DOI":"10.18632\/aging.100847","article-title":"Losing p53 loosens up ER-stress","volume":"7","author":"Byun","year":"2015","journal-title":"Aging (Albany. NY)"},{"key":"10.1016\/j.ctarc.2026.101303_bib0020","doi-asserted-by":"crossref","first-page":"4449","DOI":"10.1007\/s00018-020-03524-9","article-title":"P53 vs NF-\u03baB: the role of nuclear factor-kappa B in the regulation of p53 activity and vice versa","volume":"77","author":"Carr\u00e0","year":"2020","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ctarc.2026.101303_bib0021","doi-asserted-by":"crossref","DOI":"10.1038\/emm.2017.112","article-title":"Nutlin-3 enhances the bortezomib sensitivity of p53-defective cancer cells by inducing paraptosis","volume":"49","author":"Lee","year":"2017","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.ctarc.2026.101303_bib0022","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1007\/s12185-022-03353-5","article-title":"Multiple myeloma with high-risk cytogenetics and its treatment approach","volume":"115","author":"Hanamura","year":"2022","journal-title":"Int. J. Hematol."},{"key":"10.1016\/j.ctarc.2026.101303_bib0023","doi-asserted-by":"crossref","first-page":"20004","DOI":"10.1073\/pnas.2005052117","article-title":"Activating KRAS, NRAS, and BRAF mutants enhance proteasome capacity and reduce endoplasmic reticulum stress in multiple myeloma","volume":"117","author":"Shirazi","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.ctarc.2026.101303_bib0024","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1182\/blood-2013-05-504340","article-title":"Mutation of NRAS but not KRAS significantly reduces myeloma sensitivity to single-agent bortezomib therapy","volume":"123","author":"Mulligan","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2026.101303_bib0025","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1038\/s41392-023-01705-z","article-title":"Targeting the RAS\/RAF\/MAPK pathway for cancer therapy: from mechanism to clinical studies","volume":"8","author":"Bahar","year":"2023","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ctarc.2026.101303_bib0026","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13045-021-01079-1","article-title":"Targeting MCL-1 in cancer: current status and perspectives","volume":"14","author":"Wang","year":"2021","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.ctarc.2026.101303_bib0027","doi-asserted-by":"crossref","DOI":"10.1186\/s12967-025-07306-4","article-title":"CBX7 regulates chemotherapy-induced senescence-like growth arrest in multiple myeloma via the ERK\/STAT3\/PIM1 axis","volume":"23","author":"Ding","year":"2025","journal-title":"J. Transl. Med."},{"key":"10.1016\/j.ctarc.2026.101303_bib0028","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.molcel.2015.06.020","article-title":"ERK2 mediates metabolic stress response to regulate cell fate","volume":"59","author":"Shin","year":"2015","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ctarc.2026.101303_bib0029","doi-asserted-by":"crossref","first-page":"4126","DOI":"10.1158\/0008-5472.CAN-24-1846","article-title":"AKT and the hallmarks of cancer","volume":"84","author":"Sementino","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101303_bib0030","doi-asserted-by":"crossref","first-page":"10853","DOI":"10.1073\/pnas.0804821105","article-title":"mTORC1 promotes survival through translational control of Mcl-1","volume":"105","author":"Mills","year":"2008","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ctarc.2026.101303_bib0031","doi-asserted-by":"crossref","first-page":"157","DOI":"10.14336\/AD.2021.0729","article-title":"the emerging roles on mitochondrial function in diseases","volume":"13","author":"Xie","year":"2022","journal-title":"Aging Dis."},{"key":"10.1016\/j.ctarc.2026.101303_bib0032","doi-asserted-by":"crossref","first-page":"1426","DOI":"10.1038\/s41598-025-31265-x","article-title":"TRIP13 alters mitochondrial function and promotes bortezomib resistance in multiple myeloma","volume":"16","author":"Chen","year":"2025","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ctarc.2026.101303_bib0033","doi-asserted-by":"crossref","first-page":"1215","DOI":"10.1124\/mol.108.049114","article-title":"Dynamic effect of Bortezomib on NF-\u03bab activity and gene expression in tumor cells","volume":"74","author":"Sung","year":"2008","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.ctarc.2026.101303_bib0034","doi-asserted-by":"crossref","first-page":"9319","DOI":"10.1073\/pnas.95.16.9319","article-title":"MEKK1 activates both i\u03bab kinase \u03b1 and i\u03bab kinase \u03b2","volume":"95","author":"Lee","year":"1998","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ctarc.2026.101303_bib0035","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1186\/s12964-023-01433-5","article-title":"Interplay between proteasome inhibitors and NF-\u03bab pathway in leukemia and lymphoma: a comprehensive review on challenges ahead of proteasome inhibitors","volume":"22","author":"Pakjoo","year":"2024","journal-title":"Cell Commun. Signal"},{"key":"10.1016\/j.ctarc.2026.101303_bib0036","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1016\/S0959-437X(98)80061-0","article-title":"Ras signalling and apoptosis","volume":"8","author":"Downward","year":"1998","journal-title":"Curr. Opin. Genet. Dev."},{"key":"10.1016\/j.ctarc.2026.101303_bib0037","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1038\/sj.onc.1210679","article-title":"A pivotal role for Mcl-1 in Bortezomib-induced apoptosis","volume":"27","author":"Podar","year":"2008","journal-title":"Oncogene"},{"key":"10.1016\/j.ctarc.2026.101303_bib0038","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1161\/01.RES.86.11.1101","article-title":"Stressing rac, ras, and downstream heat shock protein 70","volume":"86","author":"Bornfeldt","year":"2000","journal-title":"Circ. Res."},{"key":"10.1016\/j.ctarc.2026.101303_bib0039","doi-asserted-by":"crossref","DOI":"10.1016\/j.neo.2022.100837","article-title":"Targeting GRP78 suppresses oncogenic KRAS protein expression and reduces viability of cancer cells bearing various KRAS mutations","volume":"33","author":"Ha","year":"2022","journal-title":"Neoplasia"},{"key":"10.1016\/j.ctarc.2026.101303_bib0040","doi-asserted-by":"crossref","first-page":"2357","DOI":"10.3390\/cells9112357","article-title":"ROS overproduction sensitises myeloma cells to Bortezomib-induced apoptosis and alleviates tumour microenvironment-mediated cell resistance","volume":"9","author":"Caillot","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ctarc.2026.101303_bib0041","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1038\/s41419-019-2192-y","article-title":"The impact of oncogenic RAS on redox balance and implications for cancer development","volume":"10","author":"Lim","year":"2019","journal-title":"Cell Death. Dis."},{"key":"10.1016\/j.ctarc.2026.101303_bib0042","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1038\/s41586-022-05475-6","article-title":"Ras drives malignancy through stem cell crosstalk with the microenvironment","volume":"612","author":"Yuan","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ctarc.2026.101303_bib0043","doi-asserted-by":"crossref","DOI":"10.1038\/oncsis.2017.36","article-title":"Molecular signaling in multiple myeloma: association of RAS\/RAF mutations and MEK\/ERK pathway activation","volume":"6","author":"Xu","year":"2017","journal-title":"Oncogenesis"},{"key":"10.1016\/j.ctarc.2026.101303_bib0044","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1038\/s41568-024-00679-6","article-title":"Combinatorial strategies to target RAS-driven cancers","volume":"24","author":"Perurena","year":"2024","journal-title":"Nat. Rev. Cancer"},{"key":"10.1016\/j.ctarc.2026.101303_bib0045","doi-asserted-by":"crossref","DOI":"10.1186\/s12964-024-01699-3","article-title":"Targeting mTOR signaling pathways in multiple myeloma: biology and implication for therapy","volume":"22","author":"Wang","year":"2024","journal-title":"Cell Commun. Signal."},{"key":"10.1016\/j.ctarc.2026.101303_bib0046","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1158\/1078-0432.CCR-20-2246","article-title":"Exploiting protein translation dependence in multiple myeloma with omacetaxine-based therapy","volume":"27","author":"Walker","year":"2021","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101303_bib0047","doi-asserted-by":"crossref","first-page":"4907","DOI":"10.1182\/blood-2005-08-3531","article-title":"Proteasome inhibitors induce a terminal unfolded protein response in multiple myeloma cells","volume":"107","author":"Obeng","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2026.101303_bib0048","doi-asserted-by":"crossref","first-page":"2011","DOI":"10.1080\/15384101.2015.1044188","article-title":"mTORC1 signaling activates NRF1 to increase cellular proteasome levels","volume":"14","author":"Zhang","year":"2015","journal-title":"Cell Cycle"},{"key":"10.1016\/j.ctarc.2026.101303_bib0049","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.63326","article-title":"The mTORC1-mediated activation of ATF4 promotes protein and glutathione synthesis downstream of growth signals","volume":"10","author":"Torrence","year":"2021","journal-title":"Elife"},{"key":"10.1016\/j.ctarc.2026.101303_bib0050","article-title":"The roles and mechanisms of SREBP1 in cancer development and drug response","volume":"11","author":"He","year":"2024","journal-title":"Genes. Dis."},{"key":"10.1016\/j.ctarc.2026.101303_bib0051","doi-asserted-by":"crossref","first-page":"3008","DOI":"10.3324\/haematol.2021.278506","article-title":"mTOR inhibitors sensitize multiple myeloma cells to venetoclax via IKZF3- and Blimp-1-mediated BCL-2 upregulation","volume":"106","author":"Osada","year":"2021","journal-title":"Haematologica"},{"key":"10.1016\/j.ctarc.2026.101303_bib0052","doi-asserted-by":"crossref","first-page":"1690","DOI":"10.1158\/0008-5472.CAN-25-3941","article-title":"Inhibition of mTOR enhances the efficacy of proteasome-dependent targeted protein degradation approaches","volume":"86","author":"Liu","year":"2026","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101303_bib0053","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1038\/s41408-025-01230-y","article-title":"High WEE1 expression is independently linked to poor survival in multiple myeloma","volume":"15","author":"Simhal","year":"2025","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ctarc.2026.101303_bib0054","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1016\/j.bbrc.2019.08.163","article-title":"Sequential combination of bortezomib and WEE1 inhibitor, MK-1775, induced apoptosis in multiple myeloma cell lines","volume":"519","author":"Barbosa","year":"2019","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.ctarc.2026.101303_bib0055","doi-asserted-by":"crossref","DOI":"10.1016\/j.critrevonc.2025.104710","article-title":"WEE1 inhibition in cancer therapy: mechanisms, synergies, preclinical insights, and clinical trials","volume":"211","author":"Thangaretnam","year":"2025","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.ctarc.2026.101303_bib0056","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1111\/bjh.16614","article-title":"The Wee1 kinase inhibitor MK1775 suppresses cell growth, attenuates stemness and synergises with bortezomib in multiple myeloma","volume":"191","author":"Liang","year":"2020","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.ctarc.2026.101303_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.leukres.2022.106967","article-title":"LncRNA MEG3 promotes the sensitivity of bortezomib by inhibiting autophagy in multiple myeloma","volume":"123","author":"Zang","year":"2022","journal-title":"Leuk. Res"},{"key":"10.1016\/j.ctarc.2026.101303_bib0058","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-018-1219-0","article-title":"LncRNA H19 overexpression induces bortezomib resistance in multiple myeloma by targeting MCL-1 via miR-29b-3p","volume":"10","author":"Pan","year":"2019","journal-title":"Cell Death. Dis."},{"key":"10.1016\/j.ctarc.2026.101303_bib0059","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejphar.2020.173752","article-title":"Lnc NEAT1\/miR-29b-3p\/Sp1 form a positive feedback loop and modulate bortezomib resistance in human multiple myeloma cells","volume":"891","author":"Che","year":"2021","journal-title":"Eur. J. Pharmacol"},{"key":"10.1016\/j.ctarc.2026.101303_bib0060","doi-asserted-by":"crossref","first-page":"788","DOI":"10.4149\/neo_2021_210205N184","article-title":"LncRNA ANRIL promotes multiple myeloma progression and bortezomib resistance by EZH2-mediated epigenetically silencing of PTEN","volume":"68","author":"Yang","year":"2021","journal-title":"Neoplasma"},{"key":"10.1016\/j.ctarc.2026.101303_bib0061","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1038\/s41375-018-0104-2","article-title":"Targeting the MALAT1\/PARP1\/LIG3 complex induces DNA damage and apoptosis in multiple myeloma","volume":"32","author":"Hu","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ctarc.2026.101303_bib0062","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.canlet.2021.01.021","article-title":"Long noncoding RNA: a resident staff of genomic instability regulation in tumorigenesis","volume":"503","author":"Guo","year":"2021","journal-title":"Cancer Lett."},{"key":"10.1016\/j.ctarc.2026.101303_bib0063","article-title":"Long noncoding RNA NORAD acts as a ceRNA mediates gemcitabine resistance in bladder cancer by sponging miR-155\u20135p to regulate WEE1 expression","volume":"228","author":"Yang","year":"2021","journal-title":"Pathol. Res. Pr."},{"key":"10.1016\/j.ctarc.2026.101303_bib0064","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.3390\/cancers14081963","article-title":"The landscape of lncRNAs in multiple myeloma: implications in the \u201challmarks of cancer\u201d, clinical perspectives and therapeutic opportunities","volume":"14","author":"Saltarella","year":"2022","journal-title":"Cancers. (Basel)"},{"key":"10.1016\/j.ctarc.2026.101303_bib0065","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1038\/s41580-020-00315-9","article-title":"Gene regulation by long non-coding RNAs and its biological functions","volume":"22","author":"Statello","year":"2021","journal-title":"Nat. Rev. Mol. Cell Biol."},{"key":"10.1016\/j.ctarc.2026.101303_bib0066","doi-asserted-by":"crossref","first-page":"1948","DOI":"10.1038\/s41375-018-0067-3","article-title":"Drugging the lncRNA MALAT1 via LNA gapmeR ASO inhibits gene expression of proteasome subunits and triggers anti-multiple myeloma activity","volume":"32","author":"Amodio","year":"2018","journal-title":"Leukemia"},{"key":"10.1016\/j.ctarc.2026.101303_bib0067","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1186\/s13046-021-02209-w","article-title":"Induction of m6A methylation in adipocyte exosomal LncRNAs mediates myeloma drug resistance","volume":"41","author":"Wang","year":"2022","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101303_bib0068","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1038\/s41419-019-1551-z","article-title":"Bortezomib-inducible long non-coding RNA myocardial infarction associated transcript is an oncogene in multiple myeloma that suppresses miR-29b","volume":"10","author":"Fu","year":"2019","journal-title":"Cell Death. Dis."},{"key":"10.1016\/j.ctarc.2026.101303_bib0069","doi-asserted-by":"crossref","first-page":"6502","DOI":"10.7150\/jca.35098","article-title":"Knockdown of long non-coding RNA PCAT-1 inhibits myeloma cell growth and drug resistance via p38 and JNK MAPK pathways","volume":"10","author":"Shen","year":"2019","journal-title":"J. Cancer"},{"key":"10.1016\/j.ctarc.2026.101303_bib0070","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188556","article-title":"Tumor suppressor p53: biology, signaling pathways, and therapeutic targeting","volume":"1876","author":"Hern\u00e1ndez Borrero","year":"2021","journal-title":"Biochim. Biophys. Acta Rev. Cancer"},{"key":"10.1016\/j.ctarc.2026.101303_bib0071","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/s41392-025-02493-4","article-title":"mTOR signaling networks: mechanistic insights and translational frontiers in disease therapeutics","volume":"10","author":"Zhang","year":"2025","journal-title":"Signal Transduct. Target. Ther."},{"key":"10.1016\/j.ctarc.2026.101303_bib0072","doi-asserted-by":"crossref","DOI":"10.1073\/pnas.2221109120","article-title":"A nucleolar long \u201cnon-coding\u201d RNA encodes a novel protein that functions in response to stress","volume":"120","author":"Feng","year":"2023","journal-title":"Proc. Natl. Acad. Sci. U S A"},{"key":"10.1016\/j.ctarc.2026.101303_bib0073","doi-asserted-by":"crossref","first-page":"3595","DOI":"10.1158\/0008-5472.CAN-18-3744","article-title":"Bortezomib stabilizes and activates p53 in proliferative compartments of both normal and tumor tissues In Vivo","volume":"79","author":"Xue","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.ctarc.2026.101303_bib0074","doi-asserted-by":"crossref","first-page":"OF1","DOI":"10.1158\/1535-7163.MCT-24-1096","article-title":"BCL-2 Family inhibition enhances mTORC1\/2 inhibition in PIK3CA -mutant colorectal cancer","volume":"24","author":"DeStefanis","year":"2025","journal-title":"Mol. Cancer Ther."},{"key":"10.1016\/j.ctarc.2026.101303_bib0075","doi-asserted-by":"crossref","first-page":"287","DOI":"10.3390\/cells9020287","article-title":"Prognosis, biology, and targeting of TP53 dysregulation in multiple myeloma","volume":"9","author":"Flynt","year":"2020","journal-title":"Cells"},{"key":"10.1016\/j.ctarc.2026.101303_bib0076","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-022-00610-y","article-title":"Clonal and subclonal TP53 molecular impairment is associated with prognosis and progression in multiple myeloma","volume":"12","author":"Martello","year":"2022","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.ctarc.2026.101303_bib0077","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1182\/blood.V128.22.3256.3256","article-title":"Inhibition of WEE1 induces cell death of both Bortezomib- and lenalidomide-resistant multiple myeloma cells: a novel therapeutic approach targeting cell-cycle checkpoint kinase","volume":"128","author":"Tabayashi","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.ctarc.2026.101303_bib0078","doi-asserted-by":"crossref","DOI":"10.3389\/fendo.2018.00218","article-title":"Soluble and cell-cell-mediated drivers of proteasome inhibitor resistance in multiple myeloma","volume":"9","author":"Farrell","year":"2018","journal-title":"Front. Endocrinol. (Lausanne)"},{"key":"10.1016\/j.ctarc.2026.101303_bib0079","doi-asserted-by":"crossref","DOI":"10.3389\/fphar.2024.1351565","article-title":"Factors determining the sensitivity to proteasome inhibitors of multiple myeloma cells","volume":"15","author":"Pelon","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ctarc.2026.101303_bib0080","doi-asserted-by":"crossref","DOI":"10.1155\/2014\/717919","article-title":"p53 Abnormalities and potential therapeutic targeting in multiple myeloma","volume":"2014","author":"Teoh","year":"2014","journal-title":"Biomed Res. Int."}],"container-title":["Cancer Treatment and Research Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002145?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2468294226002145?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T04:00:24Z","timestamp":1790913624000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2468294226002145"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026]]},"references-count":80,"alternative-id":["S2468294226002145"],"URL":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101303","relation":{},"ISSN":["2468-2942"],"issn-type":[{"value":"2468-2942","type":"print"}],"subject":[],"published":{"date-parts":[[2026]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Molecular determinants of Bortezomib sensitivity and resistance in multiple myeloma","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment and Research Communications","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctarc.2026.101303","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"101303"}}